Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - Effect of sequence

Cancer Chemotherapy and Pharmacology

Volumn 45, Issue 3, 2000, Pages 239-246

  Frei III, Emil ^a   Ara, Gulshan ^a   Teicher, Beverly ^b   Bunnell, Craig ^a   Richardson, Paul ^a   Wheeler, Catherine ^a   Tew, Kenneth ^c   Elias, Anthony ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

Alkylating agents; Melphalan; Resistance

Indexed keywords

ALKYLATING AGENT; MELPHALAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0033968988     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050035     Document Type: Article

References (37)

1. 1. Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, Anderson K, Kruskall MS, Schnipper L, Frei E III (1986) High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 4: 646
2. 2. Antman K, Eder JP, Frei E III (1987) High-dose chemotherapy with bone marrow support for solid tumors. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds) Important advances in oncology. Lippincott, Philadelphia, p 221
3. 3. Antman K, Ayash L, Elias A et al (1992) A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10: 102
4. 4. Bezwoda L, Seymour L, Dansey RD et al (1995) High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized study. J Clin Oncol 13: 2488
5. 5. Peters WP, Shpall EJ, Jones RB et al (1988) High-dose combination alkylating agents with bone marrow support as initial therapy for metastatic breast cancer. J Clin Oncol 6: 1368
6. 6. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN (1997) Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15: 3171
7. 7. Phillip T, Ladenstein R, Zucker JM et al (1993) Double megatherapy and autologous marrow transplantation for advanced neuroblastoma: the LMCE2 study. Br J Cancer 17: 119
8. 8. Ayash L, Elias A, Wheeler C et al (1994) Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor support for metastatic breast cancer: a feasibility study. J Clin Oncol 13: 2050
9. 9. Broun ER, Guidhara R, Sledge CW et al (1995) Double autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 127: 2050
10. 10. Bitran JD, Samuels B, Klein L et al (1996) Double dose intensive chemotherapy supported by hematopoietic progenitor cells yield prolonged survival in stage 4 breast cancer. Bone Marrow Transplant 127: 152
11. 11. Elias AD, Ayash L, Tepler I, Wheeler C, Schwartz G, Mazanet R, Schnipper L, Frei E 3rd, Antman K (1993) The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy. J Hematother 2: 377
12. 12. Frei E III, Cucchi C, Rosowsky A et al (1985) Alkylating agent resistance: in vitro studies of human cell lines. Proc Natl Acad Sci USA 82: 2158
13. 13. Schabel F, Trader MW, Laster WR et al (1978) Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 23: 200
14. 14. Teicher B, Cucchi C, Lee J et al (1986) Alkylating agents: In vitro studies of cross-resistance patterns in human tumor cell lines. Cancer Res 46: 437
15. 15. Frei E III, Holden S, Gonin R et al (1993) Antitumor alkylating agents: in vitro cross-resistance and collateral sensitivity studies. Cancer Chemother Pharmacol 13: 113-122
16. 16. Schabel FM, Skipper H, Trader MW et al (1983) Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 67: 905
17. 17. Schabel FM, Griswold DP, Corbett TH, Laster WR (1983) Increasing therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Pharmacol Ther 20: 282
18. 18. Teicher BA, Ara G, Keyes SR, Herbst RS, Frei E III (1998) Acute in vivo resistance in high-dose therapy. Clin Cancer Res 4: 483
19. 19. O'Brien ML, Vulevic B, Freer S, Boyd J, Shen H, Tew KD (1999) A glutathione peptidomimetic drug modulator of the multidrug resistance associated protein. (in press)
20. 20. Shen H, Kruh GD, Tew KD (1998) Increased expression of DNA-dependent protein kinase confers resistance to Adriamycin. Biochimic Biophys Acta 1381: 131
21. 21. Henderson IC (1991) Adjuvant systemic chemotherapy for early breast cancer. In: Harris JR, Hellman S, Henderson IC et al (eds) Breast diseases, 2nd edn. Lippincott, Philadelphia, p 427
22. 22. Tew KD (1994) Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 15: 4314
23. 22a. Ciaccio PJ, Tew KD (1996) Adaptive response to glutathione S-transferase inhibitors. Br J Cancer 74 [Suppl 27]: S93
24. 23. Bolton MG, Hilton J, Robertson KD, Streeper RT, Colvin OM, Noe DA (1993) Kinetic analysis of the reaction of melphalan with water, phosphate, and glutathione. Drug Metab Dispos 21: 986
25. 24. Tew KD, Bomber AM, Hoffman SJ (1988) Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622
26. 25. O'Dwyer PJ, LaCreta F, Nash S, Tinsley PW, Schilder R, Clapper ML, Tew KD, Panting L, Litwin S, Comis RL et al (1991) Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51: 6059
27. 26. Morgan AS, Ciaccio PJ, Tew KD, Kauvar LM (1996) Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 37: 363
28. 27. Colvin M (1997) Alkylating agents and platinum compounds. In: Holland JF, Frei E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer medicine, 4th edn. Williams and Wilkins, Philadelphia, p 949
29. 28. Morrow CS, Cowan K (1997) Drug resistance and its clinical circumvention. In: Holland JF, Frei E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer medicine, 4th edn. Williams and Wilkins, Philadelphia, p 794
30. 29. Tew KD, O'Brien M, Laing NM, Shen H (1998) Co-ordinate changes in the expression of protective genes in drug resistant cells. In: Ali-Osman IA, Strange R, Tew KD (eds) International conference on glutathione and glutathione-linked enzymes in human cancer and other diseases. Elsevier, New York. Chem Biol Interactions 111: 199
31. 30. Parsons PG, Carter FB, Morrison L, St. Regius N (1981) Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 41: 1525
32. 30a. Teicher BA, Frei E III (1998) Resistance to antitumor alkylating agents and cisplatin. In: Pinedo H, Giaccone G (eds) Drug resistance in the treatment of cancer. Cambridge Press, Cambridge, p 14
33. 31. Redwood WR, Colwin M (1980) Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 40: 1144
34. 32. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM (1991) Development and characterization of a melphalan resistant human multiple myeloma cell line. Cancer Res 51: 995
35. 33. Maynark K, Musk P, Daunter B, Khoo SXK, Parsons PG (1985) Melphalan resistant lymphoblastoid cell lines established from patients with ovarian cancer treated with x-linking agents. Aust J Exp Biol Med Sci 63: 333
36. 34. Alaoui-Jamali MA, Panasci L, Centurioni GM, Schecter R, Lehnert S, Batist G (1992) Nitrogen mustard-DNA interaction in melphalan-resistant mammary carcinoma cells with elevated intracellular glutathione and glutathione-S-transferase activity. Cancer Chemother Pharmacol 30: 341
37. 35. Platz EA, Nelson HH, Kelsey KT (1997) Second cancers. In: Holland JF, Frei E, Bast RC Jr, Kufe DW, Morton DL, Weichselbaum RR (eds) Cancer medicine, 4th edn. Williams and Wilkins, Philadelphia, p 2383